Intervention Review

You have free access to this content

Antibiotic treatment for Clostridium difficile-associated diarrhea in adults

  1. Richard L Nelson1,*,
  2. Philippa Kelsey2,
  3. Hayley Leeman2,
  4. Naomi Meardon2,
  5. Haymesh Patel2,
  6. Kim Paul2,
  7. Richard Rees2,
  8. Ben Taylor2,
  9. Elizabeth Wood2,
  10. Rexanna Malakun3

Editorial Group: Cochrane IBD Group

Published Online: 7 SEP 2011

Assessed as up-to-date: 12 OCT 2010

DOI: 10.1002/14651858.CD004610.pub4


How to Cite

Nelson RL, Kelsey P, Leeman H, Meardon N, Patel H, Paul K, Rees R, Taylor B, Wood E, Malakun R. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database of Systematic Reviews 2011, Issue 9. Art. No.: CD004610. DOI: 10.1002/14651858.CD004610.pub4.

Author Information

  1. 1

    Northern General Hospital, Department of General Surgery, Sheffield, Yorkshire, UK

  2. 2

    University of Sheffield, The Medical School, Sheffield, UK

  3. 3

    University of Sheffield, School of Medicine and Biomedical Sciences, Sheffield, UK

*Richard L Nelson, Department of General Surgery, Northern General Hospital, Herries Road, Sheffield, Yorkshire, S5 7AU, UK. altohorn@btinternet.com. Rick.Nelson@sth.nhs.uk.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 7 SEP 2011

SEARCH

[Figure 1]
Figure 1. Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.
[Figure 2]
Figure 2. Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Vancomycin versus Placebo, Outcome 1 Symptomatic Initial Response.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Vancomycin versus Placebo, Outcome 2 Bacteriologic Initial Response.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Metronidazole versus Vancomycin, Outcome 1 Symptomatic Initial Response.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Metronidazole versus Vancomycin, Outcome 2 Bacteriologic Initial Cure.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Metronidazole versus Vancomycin, Outcome 3 Bacteriologic Cure.
[Analysis 2.4]
Analysis 2.4. Comparison 2 Metronidazole versus Vancomycin, Outcome 4 Cure (symptomatic and bacteriologic cure).
[Analysis 2.5]
Analysis 2.5. Comparison 2 Metronidazole versus Vancomycin, Outcome 5 Symptomatic Cure minus recurrences including Zar with all exclusions treated as failures.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Bacitracin versus Vancomycin, Outcome 1 Symptomatic Initial Response.
[Analysis 3.2]
Analysis 3.2. Comparison 3 Bacitracin versus Vancomycin, Outcome 2 Symptomatic Cure.
[Analysis 3.3]
Analysis 3.3. Comparison 3 Bacitracin versus Vancomycin, Outcome 3 Bacteriologic Initial Response.
[Analysis 3.4]
Analysis 3.4. Comparison 3 Bacitracin versus Vancomycin, Outcome 4 Symptomatic Recurrence.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Teicoplanin versus Vancomycin, Outcome 1 Symptomatic Initial Response.
[Analysis 4.2]
Analysis 4.2. Comparison 4 Teicoplanin versus Vancomycin, Outcome 2 Symptomatic Cure.
[Analysis 4.3]
Analysis 4.3. Comparison 4 Teicoplanin versus Vancomycin, Outcome 3 Bacteriologic Initial Response.
[Analysis 4.4]
Analysis 4.4. Comparison 4 Teicoplanin versus Vancomycin, Outcome 4 Bacteriologic Cure.
[Analysis 4.5]
Analysis 4.5. Comparison 4 Teicoplanin versus Vancomycin, Outcome 5 Symptomatic Recurrence.
[Analysis 4.6]
Analysis 4.6. Comparison 4 Teicoplanin versus Vancomycin, Outcome 6 Bacteriologic Recurrence.
[Analysis 5.1]
Analysis 5.1. Comparison 5 Fusidic Acid versus Vancomycin, Outcome 1 Symptomatic Initial Response.
[Analysis 5.2]
Analysis 5.2. Comparison 5 Fusidic Acid versus Vancomycin, Outcome 2 Symptomatic Cure.
[Analysis 5.3]
Analysis 5.3. Comparison 5 Fusidic Acid versus Vancomycin, Outcome 3 Bacteriologic Initial Response.
[Analysis 5.4]
Analysis 5.4. Comparison 5 Fusidic Acid versus Vancomycin, Outcome 4 Bacteriologic Cure.
[Analysis 5.5]
Analysis 5.5. Comparison 5 Fusidic Acid versus Vancomycin, Outcome 5 Symptomatic Recurrence.
[Analysis 5.6]
Analysis 5.6. Comparison 5 Fusidic Acid versus Vancomycin, Outcome 6 Bacteriologic Recurrence.
[Analysis 6.1]
Analysis 6.1. Comparison 6 Nitazoxanide versus Vancomycin, Outcome 1 Symptomatic Initial Response.
[Analysis 6.2]
Analysis 6.2. Comparison 6 Nitazoxanide versus Vancomycin, Outcome 2 Recurrence of diarrhea within 31 days.
[Analysis 6.3]
Analysis 6.3. Comparison 6 Nitazoxanide versus Vancomycin, Outcome 3 Sustained response.
[Analysis 7.1]
Analysis 7.1. Comparison 7 Rifaximin versus Vancomycin, Outcome 1 Symptomatic Initial Response.
[Analysis 7.2]
Analysis 7.2. Comparison 7 Rifaximin versus Vancomycin, Outcome 2 Bacteriologic Initial Response.
[Analysis 8.1]
Analysis 8.1. Comparison 8 Metronidazole versus Nitazoxanide, Outcome 1 Initial resolution of diarrhea.
[Analysis 8.2]
Analysis 8.2. Comparison 8 Metronidazole versus Nitazoxanide, Outcome 2 Recurrence of Diarrhea at 31 d..
[Analysis 9.1]
Analysis 9.1. Comparison 9 Metronidazole versus Metronidazole + Rifampin, Outcome 1 Resolution of Diarrhea.
[Analysis 9.2]
Analysis 9.2. Comparison 9 Metronidazole versus Metronidazole + Rifampin, Outcome 2 Recurrence of diarrhea within 40 days.
[Analysis 10.1]
Analysis 10.1. Comparison 10 Metronidazole versus Teicoplanin, Outcome 1 Symptomatic Initial Response.
[Analysis 10.2]
Analysis 10.2. Comparison 10 Metronidazole versus Teicoplanin, Outcome 2 Symptomatic Cure.
[Analysis 10.3]
Analysis 10.3. Comparison 10 Metronidazole versus Teicoplanin, Outcome 3 Bacteriologic Initial Cure.
[Analysis 10.4]
Analysis 10.4. Comparison 10 Metronidazole versus Teicoplanin, Outcome 4 Bacteriologic Cure.
[Analysis 10.5]
Analysis 10.5. Comparison 10 Metronidazole versus Teicoplanin, Outcome 5 Symptomatic Recurrence.
[Analysis 11.1]
Analysis 11.1. Comparison 11 Metronidazole versus Fusidic Acid, Outcome 1 Symptomatic Initial Response.
[Analysis 11.2]
Analysis 11.2. Comparison 11 Metronidazole versus Fusidic Acid, Outcome 2 Symptomiatic Cure.
[Analysis 11.3]
Analysis 11.3. Comparison 11 Metronidazole versus Fusidic Acid, Outcome 3 Bacteriologic initial Cure.
[Analysis 11.4]
Analysis 11.4. Comparison 11 Metronidazole versus Fusidic Acid, Outcome 4 Bacteriologic Cure.
[Analysis 11.5]
Analysis 11.5. Comparison 11 Metronidazole versus Fusidic Acid, Outcome 5 Symptomatic Recurrence.
[Analysis 12.1]
Analysis 12.1. Comparison 12 Teicoplanin versus Fusidic Acid, Outcome 1 Symptomatic Initial Response.
[Analysis 12.2]
Analysis 12.2. Comparison 12 Teicoplanin versus Fusidic Acid, Outcome 2 Symptomatic Cure.
[Analysis 12.3]
Analysis 12.3. Comparison 12 Teicoplanin versus Fusidic Acid, Outcome 3 Bacteriologic Initial Cure.
[Analysis 12.4]
Analysis 12.4. Comparison 12 Teicoplanin versus Fusidic Acid, Outcome 4 Bacteriologic Cure.
[Analysis 12.5]
Analysis 12.5. Comparison 12 Teicoplanin versus Fusidic Acid, Outcome 5 Symptomatic Recurrence.
[Analysis 13.1]
Analysis 13.1. Comparison 13 Dose finding studies, Outcome 1 Symptomatic Initial Response.
[Analysis 13.2]
Analysis 13.2. Comparison 13 Dose finding studies, Outcome 2 Symptomatic Recurrence.
[Analysis 13.3]
Analysis 13.3. Comparison 13 Dose finding studies, Outcome 3 Symptomatic Cure.
[Analysis 13.4]
Analysis 13.4. Comparison 13 Dose finding studies, Outcome 4 Bacteriologic Cure.